Referências
Principais artigos
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.Texto completo
American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Association; 2021.Texto completo
Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012 Jul;13(5):318-78. Resumo
Artigos de referência
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.Texto completo
2. McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008 Nov 1;30(1):67-76.Texto completo Resumo
3. McGrath JJ. Myths and plain truths about schizophrenia epidemiology - the NAPE lecture 2004. Acta Psychiatr Scand. 2005 Jan;111(1):4-11. Resumo
4. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl. 1992;20:1-97. Resumo
5. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022 Feb;9(2):137-50.Texto completo Resumo
6. Gupta S, Murray RM. The relationship of environmental temperature to the incidence and outcome of schizophrenia. Br J Psychiatry. 1992 Jun;160:788-92. Resumo
7. Piotrowski P, Gondek TM, Królicka-Deręgowska A, et al. Causes of mortality in schizophrenia: an updated review of European studies. Psychiatr Danub. 2017 Jun;29(2):108-20.Texto completo Resumo
8. Mitchell AJ, Malone D. Physical health and schizophrenia. Curr Opin Psychiatry. 2006 Jul;19(4):432-7. Resumo
9. Fazel S, Wolf A, Palm C, et al. Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: a 38-year total population study in Sweden. Lancet Psychiatry. 2014 Jun;1(1):44-54.Texto completo Resumo
10. Torrey EF, Miller J, Rawlings R, et al. Seasonal birth patterns of neurological disorders. Neuroepidemiology. 2000 Jul-Aug;19(4):177-85. Resumo
11. McGrath JJ, Welham JL. Season of birth and schizophrenia: a systematic review and meta-analysis of data from the Southern Hemisphere. Schizophr Res. 1999 Feb 15;35(3):237-42. Resumo
12. Bota RG, Munro JS, Sagduyu K. Identification of the schizophrenia prodrome in a hospital-based patient population. Mo Med. 2005 Mar-Apr;102(2):142-6. Resumo
13. Werbeloff N, Levine SZ, Rabinowitz J. Elaboration on the association between immigration and schizophrenia: a population-based national study disaggregating annual trends, country of origin and sex over 15 years. Soc Psychiatry Psychiatr Epidemiol. 2012 Feb;47(2):303-11. Resumo
14. Bourque F, van der Ven E, Malla A. A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. Psychol Med. 2011 May;41(5):897-910. Resumo
15. National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. Oct 2016 [internet publication].Texto completo
16. Kirkbride JB, Errazuriz A, Croudace TJ, et al. Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLoS One. 2012;7(3):e31660.Texto completo Resumo
17. Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev. 1997 Oct;104(4):667-85. Resumo
18. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry. 2000 Feb 1;47(3):210-20. Resumo
19. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia - an overview. JAMA Psychiatry. 2020 Feb 1;77(2):201-10. Resumo
20. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003 Dec;60(12):1187-92.Texto completo Resumo
21. Marder SR, Cannon TD. Schizophrenia. N Engl J Med. 2019 Oct 31;381(18):1753-61. Resumo
22. Bennett MR. Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss. Prog Neurobiol. 2011 Nov;95(3):275-300.Texto completo Resumo
23. Kuswanto CN, Teh I, Lee T-S, et al. Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic review. Clin Psychopharmacol Neurosci. 2012 Apr;10(1):13-24.Texto completo Resumo
24. Huber G. Prodromal symptoms in schizophrenia [in German]. Fortschr Neurol Psychiatr. 1995 Apr;63(4):131-8. Resumo
25. McCarley RW, Wible CG, Frumin M, et al. MRI anatomy of schizophrenia. Biol Psychiatry. 1999 May 1;45(9):1099-119.Texto completo Resumo
26. Parellada E, Gassó P. Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. Transl Psychiatry. 2021 May 6;11(1):271.Texto completo Resumo
27. Kambeitz J, Kambeitz-Ilankovic L, Cabral C, et al. Aberrant functional whole-brain network architecture in patients with schizophrenia: a meta-analysis. Schizophr Bull. 2016 Jul;42(suppl 1):S13-21.Texto completo Resumo
28. Cannon TD, Chung Y, He G, et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry. 2015 Jan 15;77(2):147-57. Resumo
29. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science. 2002 Apr 26;296(5568):692-5. Resumo
30. Laruelle M. Imaging dopamine transmission in schizophrenia: a review and meta-analysis. Q J Nucl Med. 1998 Sep;42(3):211-21. Resumo
31. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol. 1999 Dec;13(4):358-71. Resumo
32. Schobel SA, Chaudhury NH, Khan UA, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013 Apr 10;78(1):81-93.Texto completo Resumo
33. Smith TE, Hull JW, Huppert JD, et al. Insight and recovery from psychosis in chronic schizophrenia and schizoaffective disorder patients. J Psychiatr Res. 2004 Mar-Apr;38(2):169-76. Resumo
34. Miller B, Messias E, Miettunen J, et al. Meta-analysis of paternal age and schizophrenia risk in male versus female offspring. Schizophr Bull. 2011 Sep;37(5):1039-47.Texto completo Resumo
35. Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia. Schizophr Bull. 2006 Jan;32(1):3-8.Texto completo Resumo
36. Macleod J, Davey Smith G, Hickman M. Does cannabis use cause schizophrenia? Lancet. 2006 Apr 1;367(9516):1055. Resumo
37. Arseneault L, Cannon M, Witton J, et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004 Feb;184:110-7. Resumo
38. Arendt M, Rosenberg R, Foldager L, et al. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005 Dec;187:510-5. Resumo
39. Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011 Mar 1;342:d738.Texto completo Resumo
40. McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry. 2010 May;67(5):440-7.Texto completo Resumo
41. Hjorthøj C, Albert N, Nordentoft M. Association of substance use disorders with conversion from schizotypal disorder to schizophrenia. JAMA Psychiatry. 2018 Jul 1;75(7):733-9.Texto completo Resumo
42. Hindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 2020 Apr;7(4):344-53.Texto completo Resumo
43. Belbasis L, Köhler CA, Stefanis N, et al. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. Acta Psychiatr Scand. 2018 Feb;137(2):88-97. Resumo
44. Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019 Aug;6(8):675-712. Resumo
45. Schoeler T, Petros N, Di Forti M, et al. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. 2017 Aug;4(8):627-33.Texto completo Resumo
46. Ziermans T, de Wit S, Schothorst P, et al. Neurocognitive and clinical predictors of long-term outcome in adolescents at ultra-high risk for psychosis: a 6-year follow-up. PLoS One. 2014 Apr 4;9(4):e93994.Texto completo Resumo
47. Mittal VA, Dean DJ, Bernard JA, et al. Neurological soft signs predict abnormal cerebellar-thalamic tract development and negative symptoms in adolescents at high risk for psychosis: a longitudinal perspective. Schizophr Bull. 2014 Nov;40(6):1204-15.Texto completo Resumo
48. Dean DJ, Bernard JA, Orr JM, et al. Cerebellar morphology and procedural learning impairment in neuroleptic-naive youth at ultrahigh risk of psychosis. Clin Psychol Sci. 2014 Mar;2(2):152-64.Texto completo Resumo
49. Bernard JA, Dean DJ, Kent JS, et al. Cerebellar networks in individuals at ultra high-risk of psychosis: impact on postural sway and symptom severity. Hum Brain Mapp. 2014 Aug;35(8):4064-78.Texto completo Resumo
50. Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull. 2003;29(4):671-92. Resumo
51. Morgan C, Fisher H. Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma - a critical review. Schizophr Bull. 2007 Jan;33(1):3-10.Texto completo Resumo
52. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Mar 2014 [internet publication].Texto completo
53. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med. 2001 Apr;31(3):381-400. Resumo
54. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry. 1999 Oct 1;46(7):899-907. Resumo
55. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med. 2003 Jan;33(1):97-110. Resumo
56. Craig TJ, Bromet EJ, Fennig S, et al. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry. 2000;157:60-66. Resumo
57. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999 Mar;56(3):241-7. Resumo
58. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD004718.Texto completo Resumo
59. Correll CU, Galling B, Pawar A, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018 Jun 1;75(6):555-65.Texto completo Resumo
60. Fusar-Poli P, Salazar de Pablo G, Correll CU, et al. Prevention of psychosis: advances in detection, prognosis, and intervention. JAMA Psychiatry. 2020 Jul 1;77(7):755-65. Resumo
61. Tsuang MT, Stone WS, Faraone SV. Understanding predisposition to schizophrenia: toward intervention and prevention. Can J Psychiatry. 2002 Aug;47(6):518-26. Resumo
62. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353-70. Resumo
63. Chan RC, Xu T, Heinrichs RW, et al. Neurological soft signs in schizophrenia: a meta-analysis. Schizophr Bull. 2010 Nov;36(6):1089-104.Texto completo Resumo
64. Herold CJ, Essig M, Schröder J. Neurological soft signs (NSS) and brain morphology in patients with chronic schizophrenia and healthy controls. PLoS One. 2020;15(4):e0231669.Texto completo Resumo
65. American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Washington, DC: American Psychiatric Association; 2021.Texto completo
66. Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020 Jan;34(1):3-78.Texto completo Resumo
67. Picchioni MM, Murray RM. Schizophrenia. BMJ. 2007 Jul 14;335(7610):91-5.Texto completo Resumo
68. Rector NA, Beck AT, Stolar N. The negative symptoms of schizophrenia: a cognitive perspective. Can J Psychiatry. 2005 Apr;50(5):247-57. Resumo
69. Chapman CL, Mullin K, Ryan CJ. Meta-analysis of the association between suicidal ideation and later suicide among patients with either a schizophrenia spectrum psychosis or a mood disorder. Acta Psychiatr Scand. 2015 Mar;131(3):162-73. Resumo
70. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53.Texto completo Resumo
71. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005 Jul;187:9-20. Resumo
72. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010 Nov;24(4 suppl):81-90.Texto completo Resumo
73. Dazzan P, Murray RM. Neurological soft signs in first-episode psychosis: a systematic review. Br J Psychiatry Suppl. 2002 Sep;43:s50-7. Resumo
74. Tosato S, Dazzan P. The psychopathology of schizophrenia and the presence of neurological soft signs: a review. Curr Opin Psychiatry. 2005 May;18(3):285-8. Resumo
75. Rossi A, De Cataldo S, Di Michele V, et al. Neurological soft signs in schizophrenia. Br J Psychiatry. 1990 Nov;157:735-9. Resumo
76. Venkatasubramanian G, Latha V, Gangadhar BN, et al. Neurological soft signs in never-treated schizophrenia. Acta Psychiatr Scand. 2003 Aug;108(2):144-6. Resumo
77. Ferruccio NP, Tosato S, Lappin JM, et al. Neurological signs at the first psychotic episode as correlates of long-term outcome: results from the AESOP-10 study. Schizophr Bull. 2021 Jan 23;47(1):118-27.Texto completo Resumo
78. World Health Organization. International statistical classification of diseases and related health problems, 11th revision (ICD-11). Chapter 6: mental, behavioural or neurodevelopmental disorders. 2022 [internet publication].Texto completo
79. Hobkirk AL, Towe SL, Lion R, et al. Primary and secondary HIV prevention among persons with severe mental illness: recent findings. Curr HIV/AIDS Rep. 2015 Dec;12(4):406-12. Resumo
80. Hughes E, Bassi S, Gilbody S, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016 Jan;3(1):40-8.Texto completo Resumo
81. Bradizza CM, Stasiewicz PR. Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. J Subst Abuse Treat. 1997 Mar-Apr;14(2):103-11. Resumo
82. American Psychiatric Association. DSM-5-TR™ update supplement to diagnostic and statistical manual of mental disorders. 5th ed. text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2023.Texto completo
83. Ebel H, Schlegel U, Klosterkötter J. Chronic schizophreniform psychosis in primary hyperparathyroidism [in German]. Nervenarzt. 1992 Mar;63(3):180-3. Resumo
84. Engelhardt. Psychosis in primary hyperparathyroidism [in German]. Internist (Berl). 1991 Dec;32(12):738. Resumo
85. Joborn C, Hetta J, Palmér M, et al. Psychiatric symptomatology in patients with primary hyperparathyroidism. Ups J Med Sci. 1986;91(1):77-87. Resumo
86. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010 Jun;133(pt 6):1655-67.Texto completo Resumo
87. Wang M, Cao X, Liu Q, et al. Clinical features of limbic encephalitis with LGI1 antibody. Neuropsychiatr Dis Treat. 2017;13:1589-96.Texto completo Resumo
88. Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018 Feb 1;141(2):348-56.Texto completo Resumo
89. Taylor DM, Gaughran F, Pillinger P. The Maudsley practice guidelines for physical health conditions in psychiatry. Hoboken, NJ: Wiley-Blackwell; 2020.
90. Amador XF, Flaum M, Andreasen NC, et al. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994 Oct;51(10):826-36. Resumo
91. Hjorthøj C, Stürup AE, McGrath JJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017 Apr;4(4):295-301. Resumo
92. Vermeulen J, van Rooijen G, Doedens P, et al. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017 Oct;47(13):2217-28. Resumo
93. Bola JR, Kao DT, Soydan H. Antipsychotic medication for early-episode schizophrenia. Schizophr Bull. 2012 Jan;38(1):23-5.Texto completo Resumo
94. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000076. Resumo
95. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012 Jul;13(5):318-78. Resumo
96. Drake RJ, Husain N, Marshall M, et al. Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study. Lancet Psychiatry. 2020 Jul;7(7):602-610.Texto completo Resumo
97. Puntis S, Minichino A, De Crescenzo F, et al. Specialised early intervention teams for recent-onset psychosis. Cochrane Database Syst Rev. 2020 Nov 2;11(11):CD013288.Texto completo Resumo
98. Bola J, Kao D, Soydan H. Antipsychotic medication for early episode schizophrenia. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD006374.Texto completo Resumo
99. Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36:94-103.Texto completo Resumo
100. Samara MT, Leucht C, Leeflang MM, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry. 2015 Jul;172(7):617-29. Resumo
101. Samara MT, Klupp E, Helfer B, et al. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. Cochrane Database Syst Rev. 2018 May 11;(5):CD011884.Texto completo Resumo
102. Leucht S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012 May 16;(5):CD008016.Texto completo Resumo
103. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012 Jun 2;379(9831):2063-71. Resumo
104. Pollack CV Jr. Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder. Curr Med Res Opin. 2016 Jul;32(7):1253-60.Texto completo Resumo
105. Correll CU, Yu X, Xiang Y, et al. Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting. Ann Clin Psychiatry. 2017 May;29(2):92-107. Resumo
106. Chan EW, Lao KSJ, Lam L, et al. Intramuscular midazolam, olanzapine, or haloperidol for the management of acute agitation: A multi-centre, double-blind, randomised clinical trial. EClinicalMedicine. 2021 Feb;32:100751.Texto completo Resumo
107. Victoroff J, Coburn K, Reeve A, et al. Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry Clin Neurosci. 2014 Fall;26(4):283-312.Texto completo Resumo
108. Keers R, Ullrich S, Destavola BL, et al. Association of violence with emergence of persecutory delusions in untreated schizophrenia. Am J Psychiatry. 2014 Mar;171(3):332-9.Texto completo Resumo
109. Stroup TS, Gerhard T, Crystal S, et al. Comparative effectiveness of adjunctive psychotropic medications in patients with schizophrenia. JAMA Psychiatry. 2019 May 1;76(5):508-15. Resumo
110. Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017 Jul 1;74(7):675-84.Texto completo Resumo
111. Masuda T, Misawa F, Takase M, et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry. 2019 Oct 1;76(10):1052-62.Texto completo Resumo
112. Potkin SG, Kane JM, Correll CU, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020 Jan 7;6(1):1.Texto completo Resumo
113. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017 Mar 1;174(3):216-29.Texto completo Resumo
114. Wagner E, Kane JM, Correll CU, et al. Clozapine combination and augmentation strategies in patients with schizophrenia - recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophr Bull. 2020 Dec 1;46(6):1459-70. Resumo
115. Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Focus (Am Psychiatr Publ). 2019 Jan;17(1):76-82.Texto completo Resumo
116. Wang G, Zheng W, Li XB, et al. ECT augmentation of clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res. 2018 Oct;105:23-32. Resumo
117. Grover S, Hazari N, Kate N. Combined use of clozapine and ECT: a review. Acta Neuropsychiatr. 2015 Jun;27(3):131-42. Resumo
118. Lally J, Tully J, Robertson D, et al. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2016 Mar;171(1-3):215-24.Texto completo Resumo
119. Melzer-Ribeiro DL, Rigonatti SP, Kayo M. Efficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized ECT – sham controlled trial. Arc Clin Psychiatr. 2017 Mar-Apr;44(2).Texto completo
120. Ahmed S, Khan AM, Mekala HM, et al. Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: A comparative meta-analysis. Heliyon. 2017 Nov;3(11):e00429.Texto completo Resumo
121. Pompili M, Lester D, Dominici G, et al. Indications for electroconvulsive treatment in schizophrenia: a systematic review. Schizophr Res. 2013 May;146(1-3):1-9.Texto completo Resumo
122. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011 Apr;127(1-3):83-92. Resumo
123. Koola MM, Wehring HJ, Kelly DL. The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. J Dual Diagn. 2012;8(1):50-61.Texto completo Resumo
124. Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013 Oct;74(10):957-65. Resumo
125. Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017 Jul 1;74(7):686-93. Resumo
126. Nielsen J, Damkier P, Lublin H, et al. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011 Jun;123(6):411-22. Resumo
127. Belgamwar RB, El-Sayeh HG. Aripiprazole vs placebo for schizophrenia. Schizophr Bull. 2012 May;38(3):382-3.Texto completo Resumo
128. Belgamwar RB, El-Sayeh HG. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD006622.Texto completo Resumo
129. Khanna P, Suo T, Komossa K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014 Jan 2;(1):CD006569.Texto completo Resumo
130. Bellantuono C, Santone G. Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder [in Italian]. Riv Psichiatr. 2012 Jan-Feb;47(1):5-20. Resumo
131. Singh J, Robb A, Vijapurkar U, et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry. 2011 Dec 15;70(12):1179-87. Resumo
132. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2004;(2):CD000967.Texto completo Resumo
133. Sparshatt A, Taylor D, Patel MX, et al. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry. 2011 Aug;72(8):1108-23. Resumo
134. Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007474.Texto completo Resumo
135. Bagnall A, Lewis RA, Leitner ML, et al. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2000;(4):CD001945.Texto completo Resumo
136. Hay A, Byers A, Sereno M, et al. Asenapine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2015 Nov 24;(11):CD011458.Texto completo Resumo
137. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011 Feb;65(2):189-210.Texto completo Resumo
138. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012 May;27(3):165-76. Resumo
139. European Medicines Agency. Questions and answers: refusal of the marketing authorisation for Fanaptum (iloperidone). Nov 2017 [internet publication].Texto completo
140. Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015 Sep 1;172(9):870-80. Resumo
141. Marder SR, Hakala MJ, Josiassen MK, et al. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr. 2017 Oct;29(5):278-90. Resumo
142. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014 Feb;152(2-3):450-7.Texto completo Resumo
143. Correll CU, Davis RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020 Apr 1;77(4):349-58.Texto completo Resumo
144. Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016 Jun 15;79(12):952-61.Texto completo Resumo
145. Nussbaum A, Stroup TS. Oral paliperidone for schizophrenia. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006369.Texto completo Resumo
146. Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD008296.Texto completo Resumo
147. Coppola DM, Melkote R, Lannie C, et al. Efficacy and safety of paliperidone extended release 1.5 mg/day - a double-blind, placebo- and active-controlled, study in the treatment of patients with schizophrenia. Psychopharmacol Bull. 2011 May 15;44(2):54-72.Texto completo Resumo
148. Citrome L. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract. 2010 Jan;64(2):216-39. Resumo
149. Maayan N, Quraishi SN, David A, et al. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015 Feb 5;(2):CD000307.Texto completo Resumo
150. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011 Mar 3;364(9):842-51.Texto completo Resumo
151. Newton R, Hustig H, Lakshmana R, et al. Practical guidelines on the use of paliperidone palmitate in schizophrenia. Curr Med Res Opin. 2012 Apr;28(4):559-67. Resumo
152. Ascher-Svanum H, Zhao F, Detke HC, et al. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia. BMC Psychiatry. 2011 Sep 23;11:152.Texto completo Resumo
153. Witte MM, Case MG, Schuh KJ, et al. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia. Curr Med Res Opin. 2012 Mar;28(3):315-23. Resumo
154. Fagiolini A, De Filippis S, Azzarelli O, et al. Intramuscular aripiprazole for the treatment of agitation in schizophrenia and bipolar disorder: from clinical research to clinical practice. J Psychopath. 2013 Mar;19(1):34-41.Texto completo
155. Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013 Mar;28(2):57-66. Resumo
156. Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013 Jan;18(1):53-66.Texto completo Resumo
157. Gründer G, Heinze M, Cordes J, et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry. 2016 Aug;3(8):717-29. Resumo
158. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012 Feb;32(1):36-45. Resumo
159. Stephenson CM, Pilowsky LS. Psychopharmacology of olanzapine: a review. Br J Psychiatry Suppl. 1999;(38):52-8. Resumo
160. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009 Oct;39(10):1591-602. Resumo
161. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009 Aug;23(8):649-59. Resumo
162. Sussman N. Choosing an atypical antipsychotic. Int Clin Psychopharmacol. 2002 Aug;17 suppl 3:S29-33. Resumo
163. Zhang Y, Dai G. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Hum Psychopharmacol. 2012 Nov;27(6):605-14. Resumo
164. Corponi F, Fabbri C, Bitter I, et al. Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019 Sep;29(9):971-85. Resumo
165. Schneider-Thoma J, Efthimiou O, Bighelli I, et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry. 2019 Sep;6(9):753-65. Resumo
166. Schneider-Thoma J, Efthimiou O, Huhn M, et al. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry. 2018 Aug;5(8):653-63. Resumo
167. Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017 Apr;37(2):138-47. Resumo
168. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654.Texto completo Resumo
169. Zhang Y, Liu Y, Su Y, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017 Nov 21;17(1):373.Texto completo Resumo
170. Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020 Dec 1;177(12):1168-78.Texto completo Resumo
171. Corponi F, Serretti A, Montgomery S, et al. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017 Nov;32(6):309-18. Resumo
172. Pajonk FG. Risperidone in acute and long-term therapy of schizophrenia - a clinical profile. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):15-23. Resumo
173. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007 Jan;13(1):13-24. Resumo
174. Komossa K, Rummel-Kluge C, Schwarz S, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626.Texto completo Resumo
175. Greenwood J, Acharya RB, Marcellus V, et al. Lumateperone: a novel antipsychotic for schizophrenia. Ann Pharmacother. 2021 Jan;55(1):98-104.Texto completo Resumo
176. Correll CU, Vanover KE, Davis RE, et al. Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophr Res. 2021 Feb;228:198-205.Texto completo Resumo
177. Briggs GG, Freeman RK, Tower V, et al. Brigg's drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 12th ed. Philadephia, PA: Lippincott Williams & Wilkins; 2021.
178. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 5: treatment and management of mental health conditions during pregnancy and postpartum. Obstet Gynecol. 2023 Jun 1;141(6):1262-88.Texto completo Resumo
179. Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ. 2016 Jan 20;532:h5918. Resumo
180. Wang Z, Brauer R, Man KKC, et al. Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021 Nov;87(11):4101-23.Texto completo Resumo
181. US Food and Drug Administration. FDA drug safety communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Feb 2011 [internet publication].Texto completo
182. US Food and Drug Administration. Medication guides database: AbbVie medication guide for Depakote extended-release tablets, tablets and sprinkle capsules. June 2021 [internet publication].Texto completo
183. American Epilepsy Society. Position statement on the use of valproate by women of childbearing potential. June 2021 [internet publication].Texto completo
184. Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016 Sep 1;173(9):876-86. Resumo
185. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry. 1996 Jun;153(6):820-2. Resumo
186. Lu ML, Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry. 2000 Aug;61(8):594-9. Resumo
187. Levkovitz Y, Menlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010 Feb;71(2):138-49. Resumo
188. Liu F, Guo X, Wu R, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014 Mar;153(1-3):169-76. Resumo
189. Xiang YQ, Zheng W, Wang SB, et al. Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2017 Jan;27(1):8-18. Resumo
190. Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev. 2012 Jan 18;(1):CD007967.Texto completo Resumo
191. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003730.Texto completo Resumo
192. Andrade C, Kisely S, Monteiro I, et al. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2015 Jan;60:14-21. Resumo
193. Bodkin JA, Siris SG, Bermanzohn PC, et al. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 2005 Feb;162(2):388-90.Texto completo Resumo
194. Rezaei F, Mohammad-Karimi M, Seddighi S, et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2013 Jun;33(3):336-42. Resumo
195. Kishi T, Matsuda Y, Iwata N. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology (Berl). 2017 Jul;234(14):2113-25. Resumo
196. Bennett AC, Vila TM. The role of ondansetron in the treatment of schizophrenia. Ann Pharmacother. 2010 Jul-Aug;44(7-8):1301-6. Resumo
197. Dondé C, Vignaud P, Poulet E, et al. Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. Acta Psychiatr Scand. 2018 Oct;138(4):289-99. Resumo
198. Opoka SM, Lincoln TM. The effect of cognitive behavioral interventions on depression and anxiety symptoms in patients with schizophrenia spectrum sisorders: a systematic review. Psychiatr Clin North Am. 2017 Dec;40(4):641-59. Resumo
199. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006 Aug;57(8):1094-101. Resumo
200. Ali SA, Mathur N, Malhotra AK, et al. Electroconvulsive therapy and schizophrenia: a systematic review. Mol Neuropsychiatry. 2019 Apr;5(2):75-83.Texto completo Resumo
201. Sinclair DJ, Zhao S, Qi F, et al. Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2019 Mar 19;(3):CD011847.Texto completo Resumo
202. Zheng W, Cao XL, Ungvari GS, et al. Electroconvulsive therapy added to non-clozapine antipsychotic medication for rreatment resistant schizophrenia: meta-analysis of randomized controlled trials. PLoS One. 2016;11(6):e0156510Texto completo Resumo
203. Read J, Bentall R. The effectiveness of electroconvulsive therapy: a literature review. Epidemiol Psichiatr Soc. 2010 Oct-Dec;19(4):333-47. Resumo
204. Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry. 2015 Jan;172(1):52-8. Resumo
205. Asher L, Patel V, De Silva MJ. Community-based psychosocial interventions for people with schizophrenia in low and middle-income countries: systematic review and meta-analysis. BMC Psychiatry. 2017 Oct 30;17(1):355.Texto completo Resumo
206. Bighelli I, Rodolico A, García-Mieres H, et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2021 Nov;8(11):969-980.Texto completo Resumo
207. Dieterich M, Irving CB, Bergman H, et al. Intensive case management for severe mental illness. Cochrane Database Syst Rev. 2017 Jan 6;(1):CD007906.Texto completo Resumo
208. Turner DT, van der Gaag M, Karyotaki E, et al. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry. 2014 May;171(5):523-38. Resumo
209. Jauhar S, McKenna PJ, Radua J, et al. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014 Jan;204(1):20-9. Resumo
210. McGurk SR, Mueser KT, Xie H, et al. Cognitive enhancement treatment for people with mental illness who do not respond to supported employment: a randomized controlled trial. Am J Psychiatry. 2015 Sep 1;172(9):852-61. Resumo
211. Kluwe-Schiavon B, Sanvicente-Vieira B, Kristensen CH, et al. Executive functions rehabilitation for schizophrenia: a critical systematic review. J Psychiatr Res. 2013 Jan;47(1):91-104. Resumo
212. Cella M, Preti A, Edwards C, et al. Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis. Clin Psychol Rev. 2017 Mar;52:43-51.Texto completo Resumo
213. Darmedru C, Demily C, Franck N. Cognitive remediation and social cognitive training for violence in schizophrenia: a systematic review. Psychiatry Res. 2017 May;251:266-74. Resumo
214. Katschnig H. Rehabilitation in schizophrenia - guidelines for including psychosocial measures [in German]. Wien Med Wochenschr. 1998;148(11-12):273-80. Resumo
215. Pharoah F, Mari J, Rathbone J, et al. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD000088.Texto completo Resumo
216. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD002831.Texto completo Resumo
217. Rodolico A, Bighelli I, Avanzato C, et al. Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2022 Mar;9(3):211-221.Texto completo Resumo
218. Hoffmann H, Jäckel D, Glauser S, et al. Long-term effectiveness of supported employment: 5-year follow-up of a randomized controlled trial. Am J Psychiatry. 2014 Nov 1;171(11):1183-90.Texto completo Resumo
219. Suijkerbuijk YB, Schaafsma FG, van Mechelen JC, et al. Interventions for obtaining and maintaining employment in adults with severe mental illness, a network meta-analysis. Cochrane Database Syst Rev. 2017 Sep 12;(9):CD011867.Texto completo Resumo
220. Carmona VR, Gómez-Benito J, Huedo-Medina TB, et al. Employment outcomes for people with schizophrenia spectrum disorder: a meta-analysis of randomized controlled trials. Int J Occup Med Environ Health. 2017 May 8;30(3):345-66.Texto completo Resumo
221. Drake RE, Frey W, Bond GR, et al. Assisting Social Security Disability Insurance beneficiaries with schizophrenia, bipolar disorder, or major depression in returning to work. Am J Psychiatry. 2013 Dec;170(12):1433-41. Resumo
222. Almerie MQ, Okba Al Marhi M, Jawoosh M, et al. Social skills programmes for schizophrenia. Cochrane Database Syst Rev. 2015 Jun 9;(6):CD009006.Texto completo Resumo
223. Zhuo C, Triplett PT. Association of schizophrenia with the risk of breast cancer incidence: a meta-analysis. JAMA Psychiatry. 2018 Apr 1;75(4):363-9.Texto completo Resumo
224. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988 Nov;39(11):1172-7. Resumo
225. Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract. 2003 Sep;9(5):344-53. Resumo
226. Labad J, Montalvo I, González-Rodríguez A, et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis. Schizophr Res. 2020 Aug;222:88-96.Texto completo Resumo
227. Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract. 2014 May;20(3):196-206. Resumo
228. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011 Aug;25(8):659-71. Resumo
229. Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017 Apr;47(6):1030-40. Resumo
230. Hagi K, Nosaka T, Dickinson D, et al. Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry. 2021 May 1;78(5):510-8.Texto completo Resumo
231. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272. Resumo
232. Fan X, Borba CP, Copeland P, et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand. 2013 Mar;127(3):217-26.Texto completo Resumo
233. Ijaz S, Bolea B, Davies S, et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry. 2018 Sep 3;18(1):275.Texto completo Resumo
234. Daumit GL, Dickerson FB, Wang NY, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013 Apr 25;368(17):1594-602.Texto completo Resumo
235. Bartels SJ, Pratt SI, Aschbrenner KA, et al. Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry. 2015 Apr;172(4):344-52.Texto completo Resumo
236. Ayerbe L, Forgnone I, Addo J, et al. Hypertension risk and clinical care in patients with bipolar disorder or schizophrenia; a systematic review and meta-analysis. J Affect Disord. 2018 Jan 1;225:665-70. Resumo
237. Bauer-Staeb C, Jörgensen L, Lewis G, et al. Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden. Lancet Psychiatry. 2017 Sep;4(9):685-93.Texto completo Resumo
238. Zaman H, Sampson SJ, Beck AL, et al. Benzodiazepines for psychosis-induced aggression or agitation. Cochrane Database Syst Rev. 2017 Dec 8;(12):CD003079.Texto completo Resumo
239. Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021 Feb 25;384(8):717-26.Texto completo Resumo
240. Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024 Jan 13;403(10422):160-70. Resumo
241. Kaul I, Sawchak S, Walling DP, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2024 Aug 1;81(8):749-56.Texto completo Resumo
242. Nair PC, Chalker JM, McKinnon RA, et al. Trace amine-associated receptor 1 (TAAR1): molecular and clinical insights for the treatment of schizophrenia and related comorbidities. ACS Pharmacol Transl Sci. 2022 Mar 11;5(3):183-8.Texto completo Resumo
243. Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020 Apr 16;382(16):1497-506.Texto completo Resumo
244. Correll CU, Koblan KS, Hopkins SC, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 2021 Dec 9;7(1):63.Texto completo Resumo
245. Dedic N, Dworak H, Zeni C, et al. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021 Dec 7;22(24):13185.Texto completo Resumo
246. Balu DT, Coyle JT. The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol. 2015 Feb;20:109-15.Texto completo Resumo
247. Fleischhacker WW, Podhorna J, Gröschl M, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021 Mar;8(3):191-201. Resumo
248. Citrome L, Preskorn SH, Lauriello J, et al. Sublingual dexmedetomidine for the treatment of acute agitation in adults with schizophrenia or schizoaffective disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2022 Oct 3;83(6):22m14447.Texto completo Resumo
249. Preskorn SH, Zeller S, Citrome L, et al. Effect of sublingual dexmedetomidine vs placebo on acute agitation associated with bipolar disorder: a randomized clinical trial. JAMA. 2022 Feb 22;327(8):727-36.Texto completo Resumo
250. Penney D, Sauvé G, Mendelson D, et al. Immediate and sustained outcomes and moderators associated with metacognitive training for psychosis: a systematic review and meta-analysis. JAMA Psychiatry. 2022 May 1;79(5):417-29.Texto completo Resumo
251. Moritz S, Menon M, Balzan R, et al. Metacognitive training for psychosis (MCT): past, present, and future. Eur Arch Psychiatry Clin Neurosci. 2022 Mar 25;1-7.Texto completo Resumo
252. Firth J, Cotter J, Carney R, et al. The pro-cognitive mechanisms of physical exercise in people with schizophrenia. Br J Pharmacol. 2017 Oct;174(19):3161-72.Texto completo Resumo
253. Firth J, Stubbs B, Rosenbaum S, et al. Aerobic exercise improves cognitive functioning in people with schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2017 May 1;43(3):546-56.Texto completo Resumo
254. Vera-Garcia E, Mayoral-Cleries F, Vancampfort D, et al. A systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia: An update. Psychiatry Res. 2015 Oct 30;229(3):828-39. Resumo
255. Cabral P, Meyer HB, Ames D. Effectiveness of yoga therapy as a complementary treatment for major psychiatric disorders: a meta-analysis. Prim Care Companion CNS Disord. 2011;13(4):PCC.0r01068.Texto completo Resumo
256. Vancampfort D, Vansteelandt K, Scheewe T, et al. Yoga in schizophrenia: a systematic review of randomised controlled trials. Acta Psychiatr Scand. 2012 Jul;126(1):12-20. Resumo
257. Broderick J, Knowles A, Chadwick J, et al. Yoga versus standard care for schizophrenia. Cochrane Database Syst Rev. 2015 Oct 21;(10):CD010554.Texto completo Resumo
258. Broderick J, Vancampfort D. Yoga as part of a package of care versus standard care for schizophrenia. Cochrane Database Syst Rev. 2017 Sep 29;(9):CD012145.Texto completo Resumo
259. Geretsegger M, Mössler KA, Bieleninik Ł, et al. Music therapy for people with schizophrenia and schizophrenia-like disorders. Cochrane Database Syst Rev. 2017 May 29;(5):CD004025.Texto completo Resumo
260. Fattahi C, Hamada K, Chiang M, et al. A narrative review of mindfulness-based therapy for schizophrenia, co-occurring substance use and comorbid cardiometabolic problems. Psychiatry Res. 2021 Feb;296:113707.Texto completo Resumo
261. Chiang M, Reid-Varley WB, Fan X. Creative art therapy for mental illness. Psychiatry Res. 2019 May;275:129-36.Texto completo Resumo
262. Cheung A, Agwu V, Stojcevski M, et al. A pilot remote drama therapy program using the co-active therapeutic theater model in people with serious mental illness. Community Ment Health J. 2022 Nov;58(8):1613-20. Resumo
263. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-858.Texto completo Resumo
264. Huxley P, Krayer A, Poole R, et al. Schizophrenia outcomes in the 21st century: a systematic review. Brain Behav. 2021 Jun;11(6):e02172.Texto completo Resumo
265. Leamy M, Bird V, Le Boutillier C, et al. Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis. Br J Psychiatry. 2011 Dec;199(6):445-52.Texto completo Resumo
266. Leendertse JCP, Wierdsma AI, van den Berg D, et al. Personal recovery in people with a psychotic disorder: a systematic review and meta-analysis of associated factors. Front Psychiatry. 2021;12:622628.Texto completo Resumo
267. Isaacs AN, Brooks H, Lawn S, et al. Effectiveness of personal recovery facilitators in adults with schizophrenia and other psychoses: a systematic review of reviews and narrative synthesis. Schizophr Res. 2022 Aug;246:132-47.Texto completo Resumo
268. Penttilä M, Jääskeläinen E, Hirvonen N, et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014 Aug;205(2):88-94.Texto completo Resumo
269. Cechnicki A, Cichocki Ł, Kalisz A, et al. Duration of untreated psychosis (DUP) and the course of schizophrenia in a 20-year follow-up study. Psychiatry Res. 2014 Nov 30;219(3):420-5.Texto completo Resumo
270. Coyle JT. Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res. 2006 Dec;10(3-4):221-33. Resumo
271. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD007253.Texto completo Resumo
272. Cubo E, Gracies JM, Benabou R, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep;58(9):1379-82.Texto completo Resumo
273. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry. 2005;66 suppl 6:5-10. Resumo
274. Mar PL, Raj SR. Orthostatic hypotension for the cardiologist. Curr Opin Cardiol. 2018 Jan;33(1):66-72. Resumo
275. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017 Aug 1;136(5):e60-e122.Texto completo Resumo
276. Gray R, Gournay K. What can we do about acute extrapyramidal symptoms? J Psychiatr Ment Health Nurs. 2000 Jun;7(3):205-11. Resumo
277. Velamoor VR, Swamy GN, Parmar RS, et al. Management of suspected neuroleptic malignant syndrome. Can J Psychiatry. 1995 Nov;40(9):545-50. Resumo
278. Klemp M, Tvete IF, Skomedal T, et al. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol. 2011 Dec;31(6):698-704. Resumo
279. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62 Suppl 7:22-31. Resumo
280. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003 Jan;28 suppl 1:83-96. Resumo
281. Das C, Mendez G, Jagasia S, et al. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry. 2012 Aug;24(3):225-39. Resumo
282. Mahmood S, Booker I, Huang J, et al. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol. 2013 Feb;33(1):90-4. Resumo
283. Mukundan A, Faulkner G, Cohn T, et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006629.Texto completo Resumo
284. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004 Dec 1;71(2-3):195-212. Resumo
285. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68 suppl 1:20-27. Resumo
286. Nunes LV, Moreira HC, Razzouk D, et al. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther. 2012;38(3):281-301. Resumo
287. Bacconi L, Gressier F. Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: a literature review [in French]. Encephale. 2017 Feb;43(1):55-61. Resumo
288. Glassman AH, Bigger JT, Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001 Nov;158(11):1774-82.Texto completo Resumo
289. Royal Pharmaceutical Society; British Medical Association. British national formulary. London: BNF Publications; 2019.Texto completo
290. Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018 Aug;138(2):101-109.Texto completo Resumo
291. Farooq S, Johal RK, Ziff C, et al. Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. Cochrane Database Syst Rev. 2017 Oct 24;(10):CD011707.Texto completo Resumo
292. Reynolds RJ, Day SM, Shafer A, et al. Mortality rates and excess death rates for the seriously mentally ill. J Insur Med. 2018;47(4):212-9. Resumo
293. Tam J, Warner KE, Meza R. Smoking and the reduced life expectancy of individuals with serious mental illness. Am J Prev Med. 2016 Dec;51(6):958-66. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal